magnesium sulfate; polyethylene glycol 3350; potassium chloride; potassium sulfate; sodium bicarbonate; sodium chloride; sodium sulfate
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
SUCLEAR is an oral solution bowel preparation containing polyethylene glycol 3350 with electrolytes (magnesium sulfate, potassium chloride, potassium sulfate, sodium bicarbonate, sodium chloride, sodium sulfate) used to cleanse the colon prior to colonoscopy or other GI procedures. It works by osmotic action to induce bowel evacuation without significant systemic absorption. This is a standard-of-care procedural preparation with high clinical utility across GI practice settings.
Mature, stable bowel prep market with moderate competitive pressure (30/100); teams are likely focused on market maintenance and operational efficiency rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Positions on SUCLEAR emphasize commercial execution, gastroenterology relationships, and market maintenance rather than innovation or expansion. This is a stable, mature product ideal for professionals seeking focused domain expertise in procedural GI care and market share defense.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo